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MicrometastasesAbstract Background: SENTIX (ENGOT-CX2/CEEGOG-CX1) is an international, multi-
centre, prospective observational trial evaluating sentinel lymph node (SLN) biopsy without
pelvic lymph node dissection in patients with early-stage cervical cancer. We report the final
preplanned analysis of the secondary end-points: SLN mapping and outcomes of intraopera-
tive SLN pathology.
Methods: Forty-seven sites (18 countries) with experience of SLN biopsy participated in SEN-
TIX. We preregistered patients with stage IA1/lymphovascular space invasion-positive to IB2
(4 cm or smaller or 2 cm or smaller for fertility-sparing treatment) cervical cancer without sus-
picious lymph nodes on imaging before surgery. SLN frozen section assessment and patholog-
ical ultrastaging were mandatory. Patients were registered postoperatively if SLN were
bilaterally detected in the pelvis, and frozen sections were negative. Trial registration:
ClinicalTrials.gov (NCT02494063).
Results: We analysed data for 395 preregistered patients. Bilateral detection was achieved in
91% (355/395), and it was unaffected by tumour size, tumour stage or body mass index, but
it was lower in older patients, in patients who underwent open surgery, and in sites with
fewer cases. No SLN were found outside the seven anatomical pelvic regions. Most SLN
and positive SLN were localised below the common iliac artery bifurcation. Single positive
SLN above the iliac bifurcation were found in 2% of cases. Frozen sections failed to detect
54% of positive lymph nodes (pN1), including 28% of cases with macrometastases and 90%
with micrometastases.
Interpretation: SLN biopsy can achieve high bilateral SLN detection in patients with tumours
of 4 cm or smaller. At experienced centres, all SLN were found in the pelvis, and most were
located below the iliac vessel bifurcation. SLN frozen section assessment is an unreliable tool
for intraoperative triage because it only detects about half of N1 cases.
ª 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1.1. Evidence before the study
We searched Medline and Embase for studies published
between January 2009 and December 2019, without
language restrictions, using the following key words:
sentinel lymph node (SLN), frozen section, SLN
detection, indocyanine green, blue dye, lymphatic
mapping and cervical cancer. Reviews and single
institutional cohort studies involving fewer than 40
subjects were excluded. We found 46 articles reporting
the bilateral SLN detection in patients with cervical
cancer. This frequency varied widely, from 55% to
100%, depending on the detection technique, study
design, cohort size and year of publication. Bilateral
mapping over 90% was only reported in single institu-
tional studies using indocyanine green. Factors influ-
encing detection included tumour size, body mass
index, surgical approach, previous neoadjuvant
chemotherapy, age and lymphovascular space invasion.
The frequency of atypical SLN localisation ranged
from 0% to 20% and included the paraaortic region in
up to 5% of cases. Some studies, however, considered
the common iliac and presacral regions to be atypical.
Twenty-one articles compared the outcomes of SLN
frozen sections and pathological ultrastaging. The false
negative frequency, taking into account only macro-
metastases and micrometastases, ranged from 0% to
45%. The studies showed significant heterogeneity in
terms of sample size, study design and the protocol
used for SLN ultrastaging.
1.2. Added value of this study
SENTIX is the largest, prospective, multicentre trial on
SLN biopsy in patients with cervical cancer. Only sites
with experience of performing SLN biopsy were eligible
to join the trial. We designed protocol to mimic current
clinical practice, without restrictions on the technique
used for SLN detection or the surgical approach. To our
knowledge, this is the first trial involving prospective
central pathology review. This, in combination with an
intensive protocol for SLN ultrastaging, facilitated
reliable detection of macrometastases and
micrometastases.
1.3. Implications of all the available evidence
The trial showed that SLN biopsy techniques can be
standardised to achieve optimal SLN pelvic mapping
(bilateral detection) in more than 90% of patients with
cervical cancers smaller than 4 cm, irrespective of the
patient’s body mass index or tumour size. At experi-
enced sites, all SLN were detected in the pelvis, and most
were found in two well-defined anatomical regions
below the iliac vessel bifurcation. The risk of isolatedpositive SLN above this anatomical landmark was less
than 2%. Frozen section is an unreliable tool for intra-
operative triage because it fails to detect about half of
cases with lymph node involvement.2. Introduction
SLN biopsy has been implemented into the standard of
care for most gynaecological cancers, including vulvar,
endometrial and cervical cancers. For cervical cancer,
SLN biopsy is currently recommended for pelvic lymph
node staging in patients with stage IA2 and lympho-
vascular space invasion in European guidelines [1], while
full pelvic lymphadenectomy is still considered the
standard of care for all early-stage cervical cancer in the
National Comprehensive Cancer Network guidelines [2].
The main motive for avoiding systematic lymph node
dissection is to decrease long-term morbidities, espe-
cially lower-leg lymphoedema [3,4]. Although the first
studies of SLN in cervical cancer were published about
20 years ago [5,6], only a few studies have focused on
patients undergoing SLN biopsy without subsequent
pelvic lymph node dissection [7].
SENTIX is the first prospective, multicentre, obser-
vational trial of SLN in patients with cervical cancer in
which the primary end-point is the oncological outcome
[8] defined as the recurrence rate at 24 months after the
surgery, which will be reached in 2021. In this article, we
report the final preplanned analysis of the secondary
end-points, including the SLN mapping and frozen
section in 395 patients.3. Methods
3.1. Study design and participants
Patients were preregistered into the study if their Inter-
national Federation of Gynecology and Obstetrics
(FIGO) stage was IA1 (with lymphovascular space in-
vasion), IA2 or IB1 according to the FIGO 2009 clas-
sification, lacked suspicious lymph nodes on
preoperative imaging, had a common histological type
(squamous cell carcinoma, adenocarcinoma or adenos-
quamous carcinoma), and the largest tumour diameter
was less than 4 cm or less than 2 cm for patients
scheduled for a fertility-sparing procedure. Preregistered
patients were registered after surgery if they met addi-
tional intraoperative criteria such as bilateral SLN
detection, no metastasis of any size found on frozen
sections and no evidence of more advanced disease
(exceeding stage IB1).
The final analysis of the secondary end-points was
performed as preplanned, once 300 patients were regis-
tered postoperatively. The detection frequency was
calculated in the broader cohort of 395 patients who
D. Cibula et al. / European Journal of Cancer 137 (2020) 69e8072were preregistered before surgery once the target of 300
registered cases was reached (Fig. 1).
The quality criteria used to assess the participating
sites were published previously [8]. The SENTIX
Steering Committee excluded two sites (2/49) because of
critical deviations from the SLN pathological assess-
ment that were identified by central pathological review.
SENTIX was conducted as a European Network of
Gynaecological Oncology Trial Groups (ENGOT) trial
(ENGOT Cx2) and was led by the Central and Eastern
European Gynaecologic Oncology Group (CEEGOG;
CEEGOG Cx1). The protocol was approved by the
institutional review board at the leading institution
(General University Hospital in Prague) in June
2016 and was subsequently approved by the institutional
review boards at all participating institutions (appendix
Supplementary Fig. 1). The study was performed ac-
cording to ENGOT Model A [9].
3.2. Procedures
3.2.1. SLN detection
The protocol for SLN detection was published previ-
ously [8]. The protocol permitted open surgery or
minimally invasive techniques, and the use of any (or
combinations) of the three main tracers: blue dye,
radiocolloid and indocyanine green. All blue, ‘hot’ or
fluorescent LN were to be removed. Patients were to be
excluded from the study if SLN were not bilaterally
identified; these patients were managed according to the
institutional guidelines.P
S
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Fig. 1. Flow chart of patients registered in the3.2.2. Definition of anatomical regions in the pelvis
Seven anatomical regions of the pelvis were identified
using anatomical landmarks [10]. If SLN were identified
in more than one region, they were to be submitted for
pathology separately. The following anatomical land-
marks defined individual anatomical regions: (a)
external iliac region (right and left): paravesical fossa
medially, psoas muscle laterally, superior ramus of the
pubic bone ventrally and common iliac artery bifurca-
tion dorsally; (b) interiliac region (also known as the
obturator region) (right and left): caudal wall of the
external iliac vein cranially, common iliac artery bifur-
cation dorsally, paravesical space medially, pubic bone
together with the levator muscle ventrally, psoas muscle
laterally and obturator vessels caudally; (c) common
iliac region (right and left): aortic bifurcation cranially,
medial aspect of the common iliac vessels medially,
psoas muscle laterally, bifurcation of common iliac
vessels ventrally and sacral bone caudally; (d) presacral
region: common iliac vessels cranially and laterally,
sacral bone caudally and the level of right common iliac
vessels bifurcation ventrally. The distribution of SLN
was assessed for anatomical levels I and II separately.
Level I was defined as below the common iliac artery
bifurcation and comprised the external iliac and inter-
iliac regions. Level II comprised the common iliac re-
gions and the presacral region.
3.2.3. Frozen sections
Intraoperative pathological assessment of all SLN was
mandatory. Intraoperatively, all SLN were grosslyatient’s consent withdrawn (n= 3)
urgery cancelled (n= 1)
ntraoperative criteria
LNnot detected bilaterally (n= 36)
LN frozen section positive (macrometastases or 
icrometastases) (n= 30)
ntra-operative signs of distant tumour spread(>1b1)(n= 8)
ther (n = 1)
econd primary cancer (n = 3)
(ovarian cancer, colon cancer, non-Hodgkin lymphoma)
rimary endometrial cancer (n = 1)
ermination of the site (n = 4)
o follow-up data available (n = 8) 
SENTIX trial. SLN, sentinel lymph node.
Table 1
Preoperative characteristics of patients (N Z 391).
Variables Value









Body mass index (continuous) (kg/mg2) 24$6 (18$7e36$1)




















Squamous cell carcinoma 277 (70$8%)
Adenocarcinoma 105 (26$9%)
Adenosquamous carcinoma 9 (2$3%)
Tumour size (preoperative imaging)
2 cm 256 (65$5%)
>2 cm 134 (34$3%)






Lymphovascular space invasion (n Z 377)
Yes 120 (31$8%)
No 251 (66$6%)
Not applicable 6 (1$6%)
Values are no. of patients (%) or median (5the95th percentile).
ECOG, Eastern Cooperative Oncology Group; FIGO, International
Federation of Gynecology and Obstetrics.
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metastasis was sent for frozen section assessment. For
unsuspected SLN, one randomly selected slice was taken
and evaluated. If frozen sections revealed metastatic
involvement, the patient was to be excluded from the
study during surgery and managed according to the
institutional guidelines.
3.2.4. SLN ultrastaging protocol
After intraoperative processing, all SLN were sent for
ultrastaging. This involved cutting two consecutive sec-
tions (4 mm thick) at 150-mm intervals from each
paraffin block until there was no LN tissue left. The first
section was stained with haematoxylin and eosin, and
the second section was examined immunohistochemi-
cally with anti-cytokeratin antibodies (AE1/AE3).
Macrometastases were defined as metastatic lesions of at
least 2 mm in diameter, micrometastases as lesions of
more than 0$2 to 2 mm or less in diameter and isolated
tumour cells as individual cells or small clusters of cells
of up to 0$2 mm in diameter (less than 200 cells) [11].
3.2.5. Central pathological review
All SLN slides with corresponding paraffin blocks and
the full pathology report from at least two patients per
site were submitted to the central laboratory at the
General University Hospital, Prague, for central review.
Any sites with major or critical deviations were asked to
submit samples and pathology reports from all enrolled
patients for a second round of assessment.
3.3. Statistical analysis
We used standard descriptive statistical analyses,
including determination of the absolute and relative
frequencies for categorical variables and the median
with the 5the95th percentile range for continuous var-
iables. Fisher’s exact test was used for between-group
comparisons of categorical variables. Logistic regression
was used to determine factors that may influence the
SLN detection frequency using the forward stepwise
algorithm in a multivariable model. The overall predic-
tive power of the model was computed by receiver
operator characteristic curve analysis by calculating the
area under the curve with 95% confidence intervals.
Two-sided aZ 0$5 was adopted as the level of statistical
significance. All analyses were performed using SPSS
25.0.0.1 (IBM Corporation 2019). This study was
registered with ClinicalTrials.gov (NCT02494063).
3.4. Role of the funding source
The Czech Research Council was not involved in the
design of the trial; in the collection, analyses or inter-
pretation of data; in the writing of the manuscript or in
the decision to publish the results.4. Results
The characteristics of the preregistered patients are
shown in Table 1. Most of the patients had stage IB1
disease (N Z 342; 88%) and tumours less than or equal
to 2 cm in the largest diameter (N Z 256; 66%). Squa-
mous cell cancer was the most frequent tumour type
(N Z 277; 71%), followed by adenocarcinoma
(N Z 105; 27%) and adenosquamous carcinoma
(N Z 9; 2%). Majority of SLN were removed by
D. Cibula et al. / European Journal of Cancer 137 (2020) 69e8074minimally invasive surgery (N Z 270; 69%), including
laparoscopic or robotic approach.
SLN were detected bilaterally in 351 patients (91%)
with a median of 3 (2e12) SLN per patient (Table 2). All
three detection techniques and their combinations were
eligible in the study; the most prevalent was a combi-
nation of blue dye and radiocolloid (N Z 141; 36%),
followed by blue dye alone (N Z 58; 15%) or indoc-
yanine green alone (N Z 59; 15%) and a combination of
blue dye and indocyanine green (N Z 51; 13%). The
mean number of SLN per patient was highest when all
three tracers were used in combination (5$28 SLN per
patient), and it was similar for the three tracers used
individually or in other combinations (2$79 to 3$97 SLN
per patient) (appendix Supplementary Table 1).
Fig. 2 shows the anatomical distribution of the
detected SLN and positive SLN. Most SLN were
detected in anatomical Level I of the pelvis (N Z 351;
90%), comprising the external iliac and interiliac regions
(appendix Supplementary Tables 2 and 3). Metastatic
involvement of the SLN was found in 62 patients,
including macrometastases, micrometastases and iso-
lated tumour cells in 29, 21 and 12 patients, respectively
(Table 3). There were no differences in the anatomical
distributions of SLN and positive SLN between the
pelvic sides. Pelvic mapping of positive SLNTable 2
SLN detection (N Z 391).
Variables Value
SLN detection per pelvic side
None or unilateral 36 (9$2%)
Bilateral 355 (90$8%)
Detection method
Not applicable 2 (0$5%)
Blue dye 58 (14$8%)
Radiocolloid 14 (3$6%)
Indocyanine green 59 (15$1%)
Blue dye þ radiocolloid 141 (36$1%)
Blue dye þ indocyanine green 51 (13$0%)
Radiocolloid þ indocyanine green 36 (9$2%)
Blue dye þ radiocolloid þ indocyanine green 30 (7$7%)







Median no. of SLN per patient 3 (2e12)
No. of patients with positive SLN
Total 62 (16$5%)
Bilateral SLN 59 (15$6%)
Unilateral SLN 3 (0$8%)





Values are no. of patients (%) or median (5the95th percentile).
SLN, sentinel lymph node.corresponded to the overall SLN distribution. SLN were
detected in Level II above the interiliac bifurcation in
only 16 (4%) patients, and only seven (2%) patients had
isolated positive SLN in this region without simulta-
neous positivity in Level I (appendix Supplementary
Table 3).
Four variables were significantly associated with
successful bilateral SLN detection in univariate analysis:
use of indocyanine green, age, surgical approach and
number of patients per site (Table 4). Only two signifi-
cant variables remained in the multivariable analysis:
age and number of patients per site (appendix
Supplementary Fig. 1, Supplementary Table 4). SLN
detection was not influenced by the patient’s body mass
index, tumour size, tumour type or lymphovascular
space invasion. However, larger tumour size and lym-
phovascular space invasion were associated with a
higher risk of SLN involvement (appendix
Supplementary Table 5).
The results of the frozen section and definitive
ultrastaging are displayed in Table 3. Of 29 patients with
macrometastases, 21 (72%) were identified by frozen
section and eight by ultrastaging. The majority of
micrometastases were detected by ultrastaging (19/21;
90%) and two by frozen sections. All 12 patients with
isolated tumour cells were detected by ultrastaging. The
sensitivity of frozen section assessment of SLN status
was 75,$9% for macrometastases and 45,$8% for N1
(macrometastases and micrometastases).5. Discussion
We achieved the highest bilateral SLN detection in
cervical cancer patients ever reported in a multicentre
trial. We hypothesise that this high detection frequency
reflects the selection of sites with prior experience of
performing SLN biopsy in patients with gynaecological
tumours. Only 9% of patients were excluded from the
trial because of failure to detect bilateral SLN in the
pelvis. Many variables were not significantly associated
with the detection frequency, most notably the patient’s
body mass index, tumour size and tumour stage. How-
ever, the detection frequency was lower in older patients
and in sites that enrolled a small number of cases. None
of the SLN were localised outside of the seven standard
anatomical regions of the pelvis. Interestingly, a sole
positive SLN above the level of iliac vessels bifurcation
was found in 2% of cases. These findings suggest that
surgical exploration of the external iliac and interiliac
regions is crucial for pelvic LN staging of cervical can-
cer. Frozen sections provided an inaccurate assessment
of SLN metastatic involvement because it failed to
detect 90% of micrometastases and nearly a third (28%)
of macrometastases. Consequently, frozen sections
yielded a low sensitivity of 46% for patients with FIGO
Fig. 2. Anatomical distribution of SLN in the pelvis. AO, aorta; CI, common iliac; EI, external iliac; II, internal iliac; SLN, sentinel lymph
node.
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micrometastases).
SENTIX is the first prospective observational multi-
centre trial powered to assess the oncological outcomes
after SLN biopsy without simultaneous pelvic lympha-
denectomy. Although survival data will not be mature
before 2021, the final analysis of secondary end-points,
including the SLN detection frequency and the accuracy
of SLN frozen sections, was preplanned in a cohort of
the first 300 registered patients.
The trial was designed to reflect current clinical
practice. Therefore, the protocol permitted all surgical
approaches and all of the main SLN detection tech-
niques. SLN frozen section evaluation was mandatory
and was performed to detect nearly all patients with
positive SLN and exclude them from the study. Only
patients in whom the bilateral SLNs were negative on
frozen sections could be registered postoperatively.
In addition to its prospective design, another strength
of the SENTIX trial was the intensive SLN ultrastaging
protocol. As we recently described, pathological pro-
tocols are often incompletely described in the literature,
and the differences between studies are so substantial
that the outcomes cannot be compared reliably [12]. Our
intention in the SENTIX trial was to minimise the risk
of missing any metastasis larger than 0$2 mm(micrometastasis). While two to four levels of paraffin
blocks are usually examined in routine practice, here,
the SLN were processed completely until no residual
tissue remained. Moreover, SENTIX was the first study
to include prospective central pathological review of
SLN in patients with cervical cancer. If any major de-
viation was identified at central review, the SLN
assessment was completed according to the protocol in a
central laboratory. The quality of SLN pathological
assessment was considered crucial for maintaining pa-
tient safety. It has been shown that patients with
micrometastases or isolated tumour cells in their SLN
may have macrometastases in other pelvic LN [13].
These patients may not be considered high-risk without
SLN ultrastaging. Furthermore, their positive LN may
not be removed, and they may not receive adjuvant
treatment. For the safety of patients, it is important that
the avoidance of full LN dissection is balanced by more
intensive pathological assessment of SLN.
As the cervix is a central pelvic organ, staging of
pelvic LN on both sides should be conducted separately.
The sensitivity of SLN status for pelvic LN staging is
greatest for patients with bilateral SLN detection.
Therefore, bilateral SLN detection was an intra-
operative inclusion criterion in the SENTIX trial [8]. A
lower detection frequency was reported in earlier studies
Table 3
SLN status assessed by frozen section and final ultrastaging (N Z 391).
Type of SLN involvement SLN status (no. of patients) SLN frozen section outcome (%)
Frozen section Ultrastaging Final statusa Sensitivity False negatives NPV
Macrometastases 21 8 29 72$4 27$6 97$8
Micrometastases 2 19 21 9$5 90$5 94$7
Isolated tumour cells 0 12 12 0 100 96$7
Macrometastases þ micrometastases 23 27 50 46$0 54$0 92$5
Macrometastases þ micrometastases þ isolated tumour cells 23 39 62 37$1 62$9 89$2
SLN, sentinel lymph node; NPV, negative prediction value.
a Combined results of frozen section and ultrastaging.
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especially for larger tumours [14,15]. In an earlier liter-
ature review published in 2013, the difference in side-
specific detection was 25% between groups with tu-
mours of less than 2 cm (nZ 768) and greater than 2 cm
(nZ 724) in size [16]. Many other factors have also been
reported to influence the detection of SLN, including
body mass index, age, surgical approach, lymphovas-
cular space invasion and previous administration of
neoadjuvant chemotherapy [17,18]. With better stand-
ardisation of SLN biopsy techniques, the differences in
detection between smaller and larger tumours has pro-
gressively decreased [19,20]. Bilateral detection was
achieved in 72% of patients in the largest retrospective
cohort of 645 patients to date [21] and in 77% of patients
in a French prospective multicentre study involving 145
patients [22] with tumours of up to 4 cm in diameter. In
a combined analysis of two French prospective studies,
conducted consecutively, a learning curve was also
apparent because the detection frequency was signifi-
cantly higher in the latter study [17].
Previous experience of SLN detection in patients with
gynaecological pelvic cancers was a prerequisite for an
institution to join the SENTIX trial. To our knowledge,
the achieved bilateral detection above 90% is the highest
reported in a multicentre study in patients with cervical
cancer. This indicates that the SLN biopsy technique
can be standardised for all patients with tumours up to
4 cm in size. An important message for routine practice
is that variables, such as body mass index, tumour size
and surgical approach, did not negatively influence SLN
detection. We found just two significant factors with a
negative impact on successful bilateral detection, namely
the number of patients per site and age. A smaller
number of patients per site and older age were associ-
ated with lower detection frequencies.
An advantage of the SLN concept is that it provides
an opportunity to identify a small number of LN at the
highest risk of involvement, allowing a frozen section to
be sent for pathological assessment [1]. The median
number of SLN per patient in our trial was 3. The
literature is, however, discrepant when it comes to the
reliability of intraoperative SLN assessment. In theFrench prospective study, frozen sections were per-
formed in 102 patients, and in these patients, it failed to
detect 70% of patients with macrometastases (4/9) or all
patients with micrometastases (4/4) [23]. In a large
retrospective cohort of 225 cases, frozen sections iden-
tified just 56% of patients with macrometastases or
micrometastases [24]. Other studies, however, reported a
higher reliability of frozen sections [25e30]. The intra-
operative technique of assessing SLN is fairly uniform
and usually involves assessment of one slice from each
SLN or from each half SLN. A higher number of sec-
tions would prolong surgery, and it may result in the
loss of a substantial part of SLN tissue that would
otherwise be available for further ultrastaging. There-
fore, the key factor that influences the sensitivity of
frozen sections is the quality of the final SLN process-
ing. More intensive ultrastaging protocols allow pa-
thologists to detect a higher number of small metastases,
which are often missed intraoperatively.
Thirty patients (8%) were excluded from our trial due
to intraoperative detection of SLN involvement (Fig. 1).
Among the total cohort of 395 preregistered patients, at
least one type of SLN involvement was found in 62
(16%) patients. The frozen sections failed to identify
54% of patients with FIGO stage N1 (i.e. macro-
metastases plus micrometastases). Our findings indicate
that intraoperative assessment is not only unable to
detect micrometastases, but also about one-third of
macrometastases. Consequently, for about half of pa-
tients in our study, information about LN involvement
was not available during surgery and was instead ob-
tained from the final pathology report several days after
surgery.
Some single-centre studies have favoured indoc-
yanine green as the tracer for SLN detection [31e33].
Comparison of the detection frequency between the
different tracers was not a preplanned end-point of our
trial. The protocol allowed each institution to use the
technique they were most comfortable with using.
Indocyanine green was indeed a significant factor asso-
ciated with a higher detection frequency in the univari-
ate analysis. However, considering the high bilateral
SLN detection in the overall cohort, the difference in
Table 4
Parameters associated with bilateral SLN detection (N Z 391).
Parameters SLN detection, no. of patients (%) OR (95% CI) p
Both sides None or one side
Technique: blue dye
No 101 (91$0%) 10 (9$0%) Reference
Yes 254 (90$7%) 26 (9$3%) 1$034 (0$481e2$222) 0$932
Technique: radiocolloid
No 152 (89$4%) 18 (10$6%) 1$336 (0$672e2$653) 0$409
Yes 203 (91$9%) 18 (8$1%) Reference
Technique: indocyanine green
No 189 (87$9%) 26 (12$1%) 2$284 (1$070e4$876) 0$033
Yes 166 (94$3%) 10 (5$7%) Reference
Number of patients registered per site
10 129 (86$0%) 21 (14$0%) 6$023 (2$015e18$005) 0$001
11e20 78 (87$6%) 11 (12$4%) 1$266 (1$609e16$926) 0$006
>20 148 (97$4%) 4 (2$6%) Reference
Age category (years)
40 147 (96$1%) 6 (3$9%) Reference
41e60 167 (92$8%) 13 (7$2%) 1$907 (0$707e5$145) 0$202
>60 41 (70$7%) 17 (29$3%) 10$159 (3$763e27$421) <0$001
Body mass index category (kg/m2)
25 202 (92$7%) 16 (7$3%) Reference
26e30 79 (86$8%) 12 (13$2%) 1$918 (0$868e4$236) 0$107
>30 74 (90$2%) 8 (9$8%) 1$365 (0$561e3$322) 0$493
ECOG performance status
0 340 (91$2%) 33 (8$8%) Reference
1 15 (83$3%) 3 (16$7%) 2$061 (0$567e7$486) 0$272
Open surgery
No 245 (93$2%) 18 (6$8%) Reference
Yes 110 (85$9%) 18 (14$1%) 2$227 (1$116e4$445) 0$023
Tumour size
2 cm 235 (91$8%) 21 (8$2%) Reference
>2 cm 119 (88$8%) 15 (11$2%) 1$411 (0$702e2$836) 0$334
Tumour type
Squamous cell 250 (90$3%) 27 (9$7%) Reference
Adenocarcinoma 98 (93$3%) 7 (6$7%) 0$661 (0$279e1$568) 0$348
Adenosquamous 7 (77$8%) 2 (22$2%) 2$646 (0$523e13$379) 0$239
Lymphovascular space invasion
Yes 114 (95$0%) 6 (5$0%) Reference
No 230 (91$6%) 21 (8$4%) 1$735 (0$681e4$417) 0$248
OR, odds ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group.
D. Cibula et al. / European Journal of Cancer 137 (2020) 69e80 77detection frequency between the tracers was less than
reported in previous smaller studies [31e34].
For surgical pelvic exploration, knowledge of the
anatomical regions with a high probability of SLN
localisation is crucial. Unnecessary dissection can lead
to retroperitoneal fibrosis and increases the risk of
postoperative complications. Our data indicate that the
majority of SLN are localised in two main regions: the
external iliac region and the interiliac region between
the external and internal iliac vessels. Both of these
regions are caudal to the iliac vessel bifurcation. The
mapping of positive SLN corresponded to the overall
distribution of detected SLN. No SLN was found
outside the seven standard anatomical regions of the
pelvis. Some earlier studies suggested that 2%e5% of
SLN are atypically localised, but the regions were not
consistently defined [19,35]. In our trial, the presacral
and common iliac regions were considered as part ofLevel II of the pelvis (between the aortic and iliac vessel
bifurcations). Importantly, no SLN was found in the
paraaortic region. We hypothesise that improvements
in SLN detection techniques have resulted in more
reliable detection in the pelvis. This trend in dimin-
ishing proportion of cases with extra-pelvic SLN
localisation is apparent in two consecutive studies from
France, in which paraaortic localisation of SLN was
reported in 5% of patients in the older study and in
1$5% of patients in a combined analysis of both trials
[35,36]. It is very unlikely that lymphatic channels from
the cervix skip the whole pelvic region and lead directly
to the paraaortic region. Importantly, only seven pa-
tients (2%) in our trial had isolated positive SLN in
anatomical Level II of the pelvis. Therefore, surgeons
should pay particular attention to the two regions
below the iliac vessel bifurcation.
D. Cibula et al. / European Journal of Cancer 137 (2020) 69e8078In conclusion, the SENTIX trial showed that a
bilateral SLN detection of over 90% can be achieved in
sites with good experience in SLN biopsy techniques.
Bilateral detection was less frequent in older patients
and in sites that registered fewer patients. Most SLN are
localised in the two anatomical regions below the iliac
vessel bifurcation, and positive SLN are very rarely (2%)
localised above this anatomical landmark (i.e. in Level
II). SLN intraoperative evaluation fails to detect about
50% of metastatic cases if both macrometastases and
micrometastases are considered LN positive.
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[22] Lécuru F, Mathevet P, Querleu D, et al. Bilateral negative sentinel
nodes accurately predict absence of lymph node metastasis in
early cervical cancer: results of the SENTICOL study. J Clin
Oncol 2011;29:1686e91.
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